We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions surrounding Oxford Biomedica Plc (OXB) this week highlighted varying sentiments regarding the company's stock prospects and potential takeover interest. A participant expressed skepticism about a £7-9 bid being adequate, while another reported selling shares, suggesting fluctuating trading dynamics. Notably, discussions revealed apprehensions regarding OXB's defenses against opportunistic bids, with sentiments emerging that the company's current share price may suggest vulnerability. This concern was echoed when one investor observed, “I have to say that the impression I took from the AGM was that there was a feeling of potential vulnerability to an opportunistic bid.”
In terms of financial outlook, speculation on OXB’s revenues for the upcoming year indicated a prediction of approximately £180 million, pointing towards a year of record revenue. Quotes such as "the behavior of the company hasn't appeared to be helping their share price" encapsulated the frustration of investors amid perceived underperformance and challenges in the market context. Despite these concerns, discussions about the company's strategic position and future prospects remained active, with hopes for a more stable and significantly valued future. Several participants highlighted the potential impact of OXB's reintegration into indices like the FT250 as a catalyst for renewed investor interest. Overall, while some investors remain hopeful about OXB's future growth, underlying worries continue to cloud investor sentiment regarding its valuation and the competitive pharmaceutical market.
Show more
Oxford Biomedica Plc (LSE: OXB) has reported several key developments in recent weeks, highlighting its ongoing strategic initiatives and governance changes. Notably, as of December 2, 2024, the company's total issued share capital stands at 105,938,933 ordinary shares, which shareholders can use for determining notification obligations under the FCA's Disclosure Guidance. Additionally, new executive compensation arrangements were announced, including the grant of long-term incentive plan (LTIP) awards to key management, scaled back by 20% as part of best practice governance.
The company is also expanding its engagement in the biopharmaceutical community, with a forthcoming free webinar scheduled for December 9, 2024, focused on the use of advanced robotics in accelerating the development of viral vector products. This reflects OXB's commitment to innovation in cell and gene therapy manufacturing. Furthermore, the Board has undergone changes with the appointment of Colin Bond as a new Non-Executive Director, effective January 1, 2025, as part of planned succession efforts. These developments demonstrate OXB's proactive approach to governance and its focus on enhancing operational capabilities within the competitive biopharmaceutical landscape.
Show more
Columbia Threadneedle Management Limited is wholly owned by Columbia Threadneedle Holdings Limited, which is wholly owned by Columbia Threadneedle Group (Management) Limited, which is wholly owned by Columbia Threadneedle Group (Holdings) Limited, which is wholly owned by Columbia Threadneedle AM (Holdings) Plc, which is wholly owned by Columbia Threadneedle (Europe) Limited, which is wholly owned by Columbia Threadneedle Investments UK International Limited, which is wholly owned by Ameriprise Financial, Inc.which which which |
Well,i'll take it as reassuring without going too deeply into the rather opaque world of holding declarations.There can be an unsatisfactory delay between time of dealing and notification of a share holding and i would guess that this share purchase was the reason why the shares shot from 390 to around 440 in short order the week before last.It could be the large buyer which Dominic C understood was in the wings a fortnight back. |
No great surprise that low, and better than the techmark index I suppose :) |
Well spotted Cousin. |
So Columbia Threadneedle (per the RNS detail) were down as 3.06% in the OXB annual report, so have built another 2% over the last 6 months or so. Their business also now includes the old F&C/I&S/BMO funds but not sure where the OXB position held. |
Ameriprise Financial, Inc. is an American diversified financial services company and bank holding company based in Minneapolis, Minnesota.[1] It provides financial planning products and services, including wealth management, asset management, insurance, annuities, and estate planning.[1]As of April 2022, more than 80% of the company's revenue came from wealth management.[1][2]Ame |
Honestly never heard of them Tricky, but |
So our accumulator is unveiled. |
Not impossible - interesting just how few firms from the health sector are linked to FTSE 250...look at the big investors in this area e.g. Mercantile IT close to zero investment in this sector and as you look at all the other names it follows a very similar pattern. |
takeiteasy, |
Not all of us.... |
All this talk about US politics has scared all the OXB punters off today - they must read into this BB that the die hards have lost interest and are bored :) |
Time to let politics go and concentrate on our favourite subject, dear OXB. Til the morning, yn y bore! Looking forward to fireworks this week!!!! |
I promise to get back to OXB tomorrow and shut up about current events (or at least give it a try). |
I have never looked to political leaders to be examples of moral rectitude or providers of moral guidance.From feted heroes of distant history,to the likes of Lloyd George and JFK,flawed individuals have achieved power.I don't even expect to learn the complete truth.Russian missiles in Cuba in 63 but no mention of US missiles in Turkey,weapons of mass destruction in Iraq ,we are drip fed selective information so we will conclude what powerful lobbies,political and military,want us to believe.I'm not a conspiracy theorist but i do believe that the powers that be,invariably connive to keep the general public pretty much in the dark,exaggerating this and underplaying that,according to their agenda.A benign dictatorship seems increasingly acceptable in my advancing years :) |
sj, |
This is just a bit of oversimplified misinformation that is popular on twitter and actually stands up to very little scrutiny. |
Yes GJ , it's amazing that anyone with 34 felony convictions and a rape conviction, who incited an insurrection, sold "Top-Secret" files to foreign nations, and an inveterate lying thief could EVER be considered a candidate for POTUS. I guess we live and learn...🤔 |
The office of President of the USA should be greater than the President who holds it. Many poor presidents have at least held the office well. Others have demeaned the office they serve. |
Harry,Yes, I did watch the videos of the riots, and they very much confirmed all that I had read and seen before.Some people acted in what appeared to be almost bemused good nature, but others were out for blood. However, five people died, so it was serious, but Trump thought not. That sums him up. I'm a full blooded right of center libertarian, but could never support a man like that, even in the face of a Harris shaped alternative.And yes, you are right about the risks of Greece: like many previously communist led countries, it has history of expropriation! My (half hearted) musings have everything in excess of living expenses simply moved straight away from the SIPP into Overseas Bonds, domiciled in Guernsey, which would remove that risk. (Anyone else here got experience of those vehicles? SIPPs and ISA's have pushed them off the radar, but with labour in power I think that may change).And yes too to your observations regarding European migration: almost (?!) as much a mess as in the UK. At the moment, Greece (Crete) is home to a huge number of (illegal) migrants from Albania, Morocco, and Georgia. Everyone else moves on, hoping to get to Germany, Sweden or the UK, which are seen as the easy touches. |
red, |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 425.00 |
Offer Price | 427.00 |
Open | 430.00 |
Shares Traded | 258,355 |
Last Trade | 16:35:13 |
Low - High | 411.50 - 430.50 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.43 |
Market Cap | 453.05M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions